We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
Read MoreHide Full Article
Key Takeaways
ABBV gained nearly 11% in a week as multiple developments boosted long-term growth confidence.
AbbVie's $10.9B Apogee deal strengthens its immunology portfolio and future competitive position.
ABBV expanded Skyrizi and Rinvoq opportunities while advancing neuroscience and oncology growth.
Shares of AbbVie (ABBV - Free Report) have gained nearly 11% in the past week, translating to roughly $43 billion in market value. The upside was driven not by a single catalyst but by several positive developments that fueled investor confidence in the company’s long-term growth prospects.
The momentum began after AbbVie unveiled its $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics. The transaction is intended to strengthen the company's immunology franchise for the next decade and beyond, while enhancing its long-term competitive position against Dupixent, the blockbuster immunology therapy jointly marketed by Sanofi (SNY - Free Report) and Regeneron (REGN - Free Report) . More importantly, the acquisition appears to have eased one of the market's biggest concerns — how AbbVie plans to sustain growth once its current blockbuster therapies, Skyrizi and Rinvoq, eventually mature.
The Apogee acquisition is only one component of AbbVie's broader strategy to reinforce its leadership in immunology. At the same time, the company continues to expand the commercial reach of its existing products through new regulatory approvals that extend their addressable markets.
Last week, AbbVie secured approvals in both the United States and Europe to expand the label for Skyrizi, allowing its use in pediatric patients with moderate-to-severe plaque psoriasis. The expanded indication broadens the drug’s addressable patient population and further strengthens one of the company's key growth drivers in immunology.
More recently, an EMA advisory committee recommended approving Rinvoq for two new autoimmune indications — alopecia areata and vitiligo — in the European Union. If approved by the European Commission, the expanded label would further reinforce AbbVie's long-term growth prospects in immunology while diversifying Rinvoq's revenue opportunity.
AbbVie’s Growth Story Goes Beyond Immunology
While immunology remains AbbVie's primary growth engine, the company is also generating meaningful momentum across other therapeutic areas. Its neuroscience franchise continues to expand and is becoming an increasingly important contributor to revenue growth. One of the key drivers is Vyalev, the company's Parkinson's disease therapy, which is expected to surpass $1 billion in annual global sales despite launching in the United States only last year.
Shares of AbbVie have slightly underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.73 times forward earnings, lower than its industry’s average of 18.77.
Image Source: Zacks Investment Research
EPS estimates for 2026 and 2027 have declined in the past 30 days.
View the Zacks #1 Rank List
Image: Shutterstock
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
Key Takeaways
Shares of AbbVie (ABBV - Free Report) have gained nearly 11% in the past week, translating to roughly $43 billion in market value. The upside was driven not by a single catalyst but by several positive developments that fueled investor confidence in the company’s long-term growth prospects.
The momentum began after AbbVie unveiled its $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics. The transaction is intended to strengthen the company's immunology franchise for the next decade and beyond, while enhancing its long-term competitive position against Dupixent, the blockbuster immunology therapy jointly marketed by Sanofi (SNY - Free Report) and Regeneron (REGN - Free Report) . More importantly, the acquisition appears to have eased one of the market's biggest concerns — how AbbVie plans to sustain growth once its current blockbuster therapies, Skyrizi and Rinvoq, eventually mature.
The Apogee acquisition is only one component of AbbVie's broader strategy to reinforce its leadership in immunology. At the same time, the company continues to expand the commercial reach of its existing products through new regulatory approvals that extend their addressable markets.
Last week, AbbVie secured approvals in both the United States and Europe to expand the label for Skyrizi, allowing its use in pediatric patients with moderate-to-severe plaque psoriasis. The expanded indication broadens the drug’s addressable patient population and further strengthens one of the company's key growth drivers in immunology.
More recently, an EMA advisory committee recommended approving Rinvoq for two new autoimmune indications — alopecia areata and vitiligo — in the European Union. If approved by the European Commission, the expanded label would further reinforce AbbVie's long-term growth prospects in immunology while diversifying Rinvoq's revenue opportunity.
AbbVie’s Growth Story Goes Beyond Immunology
While immunology remains AbbVie's primary growth engine, the company is also generating meaningful momentum across other therapeutic areas. Its neuroscience franchise continues to expand and is becoming an increasingly important contributor to revenue growth. One of the key drivers is Vyalev, the company's Parkinson's disease therapy, which is expected to surpass $1 billion in annual global sales despite launching in the United States only last year.
AbbVie is also strengthening its oncology portfolio. Last month, the company secured approval for Decnupaz to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. The oncology franchise remains anchored by Venclexta and Elahere, providing another avenue for sustained long-term growth.
ABBV’s Stock Performance, Valuation and Estimates
Shares of AbbVie have slightly underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.73 times forward earnings, lower than its industry’s average of 18.77.
Image Source: Zacks Investment Research
EPS estimates for 2026 and 2027 have declined in the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.